Drug Profile
Research programme: neurodegenerative disease therapeutics and diagnostics - Neuro-Bio
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Neuro-Bio
- Class Antidementias; Calcium regulators; Neuropeptides
- Mechanism of Action Acetylcholinesterase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in United Kingdom
- 04 May 2017 Early research in Neurodegenerative disorders in United Kingdom before May 2017 (unspecified route)
- 22 Mar 2017 Neurodegenerative disease therapeutics and diagnostics - Neuro-Bio is available for licensing as of 01 May 2016. http://neuro-bio.com